This is the amplicon context sequence in accordance with the minimum information for the publication of real-time quantitative PCR experiements (MIQE) guidelines. For more details, please refer to the following publication, "Primer Sequence Disclosure: A Clarification of the MIQE Guidelines."
Gene Name: Dubious open reading frame unlikely to encode a protein, based on available experimental and comparative sequence data; partially overlaps the verified gene TKL2
Bio-Rad collaborated with Biogazelle, leaders in real-time PCR research, to design and experimentally validate PCR primers for gene expression assays across the human and mouse transcriptomes. All PCR primers were designed to meet stringent performance standards following the MIQE guidelines (minimum information for publication of quantitative real-time PCR experiments; Bustin et al. 2009).
Linear Dynamic Range Minimum of six orders of magnitude. Detection of a synthetic template standard curve from 20 to 20 million copies.
PrimePCR disease state panels were designed by referencing the National Library of Medicine database. Disease state panels allow for the thorough investigation of differentially expressed genes within a specified pathology.
The resulting gene scores were used to design real-time PCR panels. For diseases with a large number of gene targets, multiple tiered plates are available. Tier 1 plates represent the highest ranked targets with subsequent tiers containing the lower ranked or less well characterized targets.
Terms of Use of Thomson Reuters (Scientific) Inc. Maps. All users agree that (a) no right, title or interest in the Maps is transferred by display of the Maps; (b) the Maps may only be used for purposes of determining whether to purchase Bio-Rad products and services displayed in relation to the Maps; (c) the Maps may not be copied, printed, downloaded, modified or disassembled, and no derivatives of the Maps may be created; (d) the Maps and the data contained in the Maps may not be used for purposes of development or commercialization of any third party product or service without first obtaining a separate written license for such use from Thomson Reuters (Scientific) Inc.